Anti-VEGF agents in the treatment of diabetic macular edema

Vi, Konenkov; Иосифович, Коненков Владимир; Климонтов, В. В.; Валерьевич, Климонтов Вадим; Черных, В. В.; Вячеславович, Черных Валерий; Tjan, N. V.; Викторовна, Тян Надежда

doi:10.14341/dm2013478-84

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) is a full-length monoclonal humanized antibody, whereas ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) is a fragment of the above antibody. Both of them bind all isoforms of VEGF-A, but the use of bevacizumab remains off-label in ophthalmology [12,13,14,15].…”

Section: Discussionmentioning

confidence: 99%

Untitled

2021

Oftalmol Zh

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Untitled

2021

Oftalmol Zh

View full text Add to dashboard Cite

Use of Optical Coherence Tomography for Evaluation of the Results of the Treatment of Diabetic Macular Edema with Laser Coagulation of the Ocular Fundus Tissues and Intravitreal Injection of Ranibizumab (Lucentis)

Batischeva¹,

Колбенев²,

Nugaeva³

et al. 2015

Sovrem Tehnol Med

View full text Add to dashboard Cite

One of the most informative methods of noninvasive investigation of the retina is optical coherence tomography (OCT). OCT is successfully applied to the diagnosis of diabetic retinopathy especially if there is diabetic macular edema (DME).the objective of the investigation is evaluating the results of the treatment of DME with laser coagulation of the ocular fundus tissues and intravitreal injection of ranibizumab (Lucentis), on the basis of imaging data derived from OCT.Materials and Methods. Examination, treatment and dynamic observations were carried out on 108 patients (214 eyes at the stage of proliferative diabetic retinopathy with clinically relevant DME); they included 68 women and 40 men. The patients were divided into three groups depending on the overall term of DME occurrence: group I -up to 1 month (73 eyes), group II -from 1 to 3 months (69 eyes), group III -3 months or longer (72 eyes). Within each group, all the patients were divided into three subgroups which underwent either intravitreal injection of ranibizumab, or laser coagulation of the eye fundus tissues, or both treatments combined. The effectiveness of the treatment was evaluated on the basis of OCT and visometry data recorded at both 5 days and 1 month.Results. According to OCT of retina, the effect of the intravitreal injection of Lucentis alone was considerable but unstable. In the case of DME having been present for less than 1 month, the combined treatment was the most effective. In cases where DME had been present for 1 to 3 months or for more than 3 months, both laser-only and the combined treatment are effective. conclusion. We have therefore shown that choice of optimum treatment is dependent on the previous duration of DME and that OCT is a highly informative method for evaluation of DME.

show abstract

The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy

Evgrafov

Kudasheva

2022

Oftalʹmologiâ

View full text Add to dashboard Cite

Diabetic retinopathy (DR) have been taking a leading position among retinal disorders, causing a persistent and significant decrease in visual functions. The base of the disease is a retinal vascular microangiopathy, which induces a tissue ischemia and excessive production of vascular endothelial growth factors. The main method of treatment for this pathology is a laser photocoagulation. However, it is not always possible to perform appropriate laser photocoagulation, by that limiting its efficacy (cases of hard cataract and hemophthalmos). In addition, this type of treatment might have a number of serious complications, such as macular oedema, recurrent vitreous hemorrhages, the occurrence of fibrosis, atrophic changes in the retina, which leads to a decline in visual acuity and contrast sensitivity, worsening the visual field. Over the past 10 years, vascular endothelial growth factor inhibitors have been introduced into clinical practice, and showed their benefits in the treatment of disorders leading to a pathological angiogenesis. But due to the limited number of systematic observations, assessing the impact of these drugs, is necessary to investigate their efficacy and safety in patients with proliferative DR, in order to develop indications for their use. The purpose of the review is evaluation of the effect of vascular endothelial growth factor inhibitors on active neovascularization in patients with proliferative diabetic retinopathy. There is a literature of international clinical guidelines, randomized clinical trials with a varying level of evidence, articles and publications by groups of authors in the article.

show abstract

Anti-VEGF agents in the treatment of diabetic macular edema

Cited by 3 publications

References 40 publications

Untitled

Untitled

Use of Optical Coherence Tomography for Evaluation of the Results of the Treatment of Diabetic Macular Edema with Laser Coagulation of the Ocular Fundus Tissues and Intravitreal Injection of Ranibizumab (Lucentis)

The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy

Contact Info

Product

Resources

About